Anna Margaret Schmoker

Dr. Anna Margaret Schmoker

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2024 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
YLYen-Der Li
Yen-Der Li
MMMichelle W. Ma
Michelle W. Ma
MHMuhammad Murtaza Hassan
Muhammad Murtaza Hassan
MHMoritz Hunkeler
Moritz Hunkeler
MTMingxing Teng
Mingxing Teng
BEBenjamin L. Ebert
Benjamin L. Ebert
Molecular glues are proximity-inducing small molecules that have emerged as an attractive therapeutic approach. However, developing molecular glues remains challenging, requiring innovative mechanistic strategies to stabilize neoprotein interfaces and expedite discovery. Here we unveil a trans-labeling covalent molecular glue mechanism, termed ‘template-assisted covalent modification’. We identified a new series of BRD4 molecular glue degraders that recruit CUL4DCAF16 ligase to the second bromodomain of BRD4 (BRD4BD2). Through comprehensive biochemical, structural and mutagenesis analyses, we elucidated how pre-existing structural complementarity between DCAF16 and BRD4BD2 serves as a template to optimally orient the degrader for covalent modification of DCAF16Cys58. This process stabilizes the formation of BRD4–degrader–DCAF16 ternary complex and facilitates BRD4 degradation. Supporting generalizability, we found that a subset of degraders also induces GAK–BRD4BD2 interaction through trans-labeling of GAK. Together, our work establishes ‘template-assisted covalent modification’ as a mechanism for covalent molecular glues, which opens a new path to proximity-driven pharmacology.

9 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
TBTyler S. Beyett
Tyler S. Beyett
CTCiric To
Ciric To
DHDavid E. Heppner
David E. Heppner
JRJaimin K. Rana
Jaimin K. Rana
ASAnna Margaret Schmoker
Anna Margaret Schmoker
MEMichael J. Eck
Michael J. Eck
Lung cancer is frequently caused by activating mutations in the epidermal growth factor receptor (EGFR). Allosteric EGFR inhibitors offer promise as the next generation of therapeutics, as they are unaffected by common ATP-site resistance mutations and synergize with the drug osimertinib. Here, we examine combinations of ATP-competitive and allosteric inhibitors to better understand the molecular basis for synergy. We identify a subset of irreversible EGFR inhibitors that display positive binding cooperativity and synergy with the allosteric inhibitor JBJ-04-125-02 in several EGFR variants. Structural analysis of these complexes reveals conformational changes occur mainly in the phosphate-binding loop (P-loop). Mutation of F723 in the P-loop reduces cooperative binding and synergy, supporting a mechanism in which F723-mediated contacts between the P-loop and the allosteric inhibitor are critical for synergy. These structural and mechanistic insights will aid in the identification and development of additional inhibitor combinations with potential clinical value.

7 September 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GPGonzalo Luis Gonzalez-Del Pino
Gonzalo Luis Gonzalez-Del Pino
KLKunhua Li
Kunhua Li
EPEunyoung Park
Eunyoung Park
ASAnna Margaret Schmoker
Anna Margaret Schmoker
BHByung Hak Ha
Byung Hak Ha
MEMichael J. Eck
Michael J. Eck
Significance: Drugs that inhibit specific kinases now represent one of the main classes of targeted therapies. A majority of drug development efforts in this space focus on a given kinase in isolation as the target. However, our work demonstrates that in the context of the RAF/MEK/ERK pathway, the relevant target for compounds developed as allosteric MEK inhibitors (MEKi) is not free MEK but RAF/MEK complexes. Because signaling through this pathway is essential in normal tissues, indiscriminate blockade of all MEK activity is not tolerated. Our findings imply that selective inhibition of specific RAF/MEK complexes is an accessible route for development of new MEKi, and they provide a biophysical foundation for better understanding and applying current clinical agents.

24 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
KBKheewoong Baek
Kheewoong Baek
RMRebecca J. Metivier
Rebecca J. Metivier
SBShourya S. Roy Burman
Shourya S. Roy Burman
JBJonathan W. Bushman
Jonathan W. Bushman
HYHojong Yoon
Hojong Yoon
EFEric S. Fischer
Eric S. Fischer
Induced proximity by molecular glues refers to strategies that leverage the recruitment of proteins to facilitate their modification, regulation or degradation. As prospective design of molecular glues remains challenging, unbiased discovery methods are necessary to discover new chemical targets. Here we establish a high throughput affinity proteomics workflow leveraging E3 ligase activity-impaired CRBN-DDB1ΔB in cell lysates for the unbiased identification of molecular glue targets. By mapping the interaction landscape of CRBN-binding molecular glues, we unveil 298 protein targets and demonstrate the utility of enrichment methods for identifying targets overlooked by established methods. We use a computational workflow to estimate target confidence and perform biochemical and structural validation of uncharacterized neo-substrates. We further identify a lead compound for the previously untargeted non-zinc finger PPIL4 through a biochemical screen. Our study provides a comprehensive inventory of targets chemically recruited to CRBN and delivers a robust and scalable workflow for identifying drug-induced protein interactions in cell lysates.

29 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
EPEunyoung Park
Eunyoung Park
SRShaun Rawson
Shaun Rawson
ASAnna Margaret Schmoker
Anna Margaret Schmoker
BKByeong-Won Kim
Byeong-Won Kim
SOSehee Oh
Sehee Oh
MEMichael J. Eck
Michael J. Eck
RAF-family kinases are activated by recruitment to the plasma membrane by GTP-bound RAS, whereupon they initiate signaling through the MAP kinase cascade. Prior structural studies of KRAS with RAF have focused on the isolated RAS-binding and cysteine-rich domains of RAF (RBD and CRD, respectively), which interact directly with RAS. Here we describe cryo-EM structures of a KRAS bound to intact BRAF in an autoinhibited state with MEK1 and a 14-3-3 dimer. Analysis of this KRAS/BRAF/MEK1/14-3-3 complex reveals KRAS bound to the RAS-binding domain of BRAF, captured in two orientations. Core autoinhibitory interactions in the complex are unperturbed by binding of KRAS and in vitro activation studies confirm that KRAS binding is insufficient to activate BRAF, absent membrane recruitment. These structures illustrate the separability of binding and activation of BRAF by RAS and suggest stabilization of this pre-activation intermediate as an alternative therapeutic strategy to blocking binding of KRAS.

1 September 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
DJDong Man Jang
Dong Man Jang
KBKayla Boxer
Kayla Boxer
BHByung Hak Ha
Byung Hak Ha
ETEmre Tkacik
Emre Tkacik
TLTalya Levitz
Talya Levitz
MEMichael J. Eck
Michael J. Eck
CRAF (RAF1) is one of three RAF-family kinases that initiate MAP kinase signaling in response to activated RAS and is essential for oncogenic signaling from mutant KRAS. Like BRAF, CRAF is regulated by 14-3-3 engagement and by intramolecular autoinhibitory interactions of its N-terminal regulatory region. Unlike BRAF, it is thought to require tyrosine phosphorylation in its N-terminal acidic (NtA) motif for full catalytic activation. Here we describe cryo-EM reconstructions of full-length CRAF in complex with MEK1 and a 14-3-3 dimer. These structures reveal a fully autoinhibited conformation analogous to that observed for BRAF and two “open monomer” states in which the inhibitory interactions of the CRD and 14-3-3 dimer are released or rearranged, but the kinase domain remains inactive. Structure-function studies of the NtA motif indicate that phosphorylation or acidic mutations in this segment increase catalytic activity by destabilizing the inactive conformation of the kinase domain. Collectively, these studies provide a structural foundation for understanding the shared and unique regulatory features of CRAF and will inform efforts to selectively block CRAF signaling in cancer.